Try our Advanced Search for more refined results

Novartis To Buy Merck Spin-Off Calypso Biotech For Up To $375M

By Yeji Jesse Lee (January 8, 2024, 6:01 PM EST) -- Swiss pharmaceutical giant Novartis is buying European company Calypso Biotech in a deal that could be worth up to $375 million, according to an announcement from Calypso on Monday, marking one of the earliest deals to be announced at the start of the deal frenzy expected at the J.P. Morgan Healthcare conference in San Francisco this week....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!